Urine test to detect liver cancer return after surgery
Part of Cancer, Digestive system clinical trials.
This study tests if a simple urine test can help find early signs of liver cancer coming back after surgery. Patients with early-stage liver cancer who have surgery may join to help improve follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer that is at an early stage (BCLC stage 0, A, or B) and can be removed with surgery.
- You have not received any other cancer treatment before surgery.
- You do not have kidney or urinary tract disease.
- You do not have more than one tumor at the same time.
- Your cancer started in the liver (not spread from another part of the body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a blood test (measuring a protein called AKR1B10) can help detect if liver cancer comes back after surgery. It may help doctors monitor patients more closely after tumor removal.
This study uses a blood test that looks for signs of liver cancer coming back after treatment. It may help doctors find recurrence early and plan better care.
This trial studies a new blood test that looks for DNA from cancer cells' mitochondria to see if it can catch liver cancer coming back earlier. The goal is to help doctors find recurrence faster and improve follow-up care.
This trial uses a simple blood test to check for signs of liver cancer coming back after surgery. It may help doctors catch a return earlier and guide further treatment.
This trial is for people with early-stage liver cancer who are scheduled for surgery. It uses a simple blood test to look for tiny bits of tumor DNA after treatment, which may help predict if the cancer will come back.
This study checks whether a simple blood test (called ctDNA) can predict if liver cancer will come back after surgery. It compares the blood test to a standard lab result from the removed tumor, which may help doctors plan better follow-up care.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.